SignalXSignalX

GKOS GLAUKOS Corp

Q3 2025 10-Q
Filed: Oct 31, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR
GLAUKOS Corp Overview

GLAUKOS Corp (GKOS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 31, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: MIGS restrictions by five MACs limiting iStent sales volume, impacting U.S. glaucoma product revenue growth
  • • Updated operational risk: $80M+ planned capital expenditure for new Huntsville, AL R&D and manufacturing facility starting 2026
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$134M

Net Income

-$16M

Gross Margin

78.4%

Operating Margin

-12.3%

Net Margin

-12.2%

ROE

-2.1%

Total Assets

$999M

Source: XBRL data from GLAUKOS Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on GLAUKOS Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.